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Abstract
Background: The performance of serum biomarkers for the early detection of invasive aspergillosis expectedly depends on
the timing of test results relative to the empirical administration of antifungal therapy during neutropenia, although a
dynamic evaluation framework is lacking.
Methods: We developed a multi-state model describing simultaneously the likelihood of empirical antifungal therapy and
the risk of invasive aspergillosis during neutropenia. We evaluated whether the first positive test result with a biomarker is
an independent predictor of invasive aspergillosis when both diagnostic information used to treat and risk factors of
developing invasive aspergillosis are taken into account over time. We applied the multi-state model to a homogeneous
cohort of 185 high-risk patients with acute myeloid leukemia. Patients were prospectively screened for galactomannan
antigenemia twice a week for immediate treatment decision; 2,214 serum samples were collected on the same days and
blindly assessed for (1-.3)- b-D-glucan antigenemia and a quantitative PCR assay targeting a mitochondrial locus.
Results: The usual evaluation framework of biomarker performance was unable to distinguish clinical benefits of b-glucan
or PCR assays. The multi-state model evidenced that the risk of invasive aspergillosis is a complex time function of
neutropenia duration and risk management. The quantitative PCR assay accelerated the early detection of invasive
aspergillosis (P= .010), independently of other diagnostic information used to treat, while b-glucan assay did not (P= .53).
Conclusions: The performance of serum biomarkers for the early detection of invasive aspergillosis is better apprehended
by the evaluation of time-varying predictors in a multi-state model. Our results provide strong rationale for prospective
studies testing a preemptive antifungal therapy, guided by clinical, radiological, and bi-weekly blood screening with
galactomannan antigenemia and a standardized quantitative PCR assay.
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Introduction
The evaluation of biomarker performance to detect invasive
aspergillosis is often limited by the absence of the gold standard for
diagnosis and the empirical administration of antifungal therapy
for a persistent or recurrent fever. As a case study, patients treated
with chemotherapy for acute myeloid leukemia are at high risk of
developing invasive aspergillosis that portends poor prognosis [1].
Invasive aspergillosis is rarely proven by direct microbiological
detection or autopsy, and often remains a possible or a probable
diagnosis depending on a combination of clinical, radiological, and
microbiological criteria [2,3]. Moreover, the risk of invasive
aspergillosis evolves over time as it increases with neutropenia
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duration [4,5], while it purposely decreases with the empirical
administration of antifungal therapy [6]. Accordingly, the
performance of biomarkers to detect invasive aspergillosis depends
on the timing of test results during neutropenia [7]. The need to
evaluate biomarker performance is particularly important in
untreated patients because serial blood screening may accelerate
the early detection of invasive aspergillosis, independently of other
diagnostic information [8–11].
Aspergillus galactomannan antigen is the biomarker that is most
often used in current practice to detect invasive aspergillosis in
leukemic patients [12]. Galactomannan antigen detection was
added by consensus to the indirect microbiological criteria of a
probable invasive fungal disease in 2002 [2]. Serial blood
screening with galactomannan antigen has been increasingly used
to guide the early administration of antifungal therapy [13,14] and
to monitor treatment [15,16]. The experience with (1-.3)-b-D-
glucan (b-glucan) antigenemia or PCR assays is more limited. b-
glucan antigenemia was recently incorporated in the definition of a
probable invasive fungal disease [3], although b-glucan is not
specific of Aspergillus spp. [17,18]. PCR assays targeting Aspergillus
DNA are even less accepted in routine practice given the lack of
common protocols [3].
Meta-analyses found a marked heterogeneity between diagnos-
tic studies for all biomarkers [19–23]. Several time-invariant
confounders of biomarker performance were consistently identi-
fied: distinct features of each biomarker such as the cutoff level
used to define a positive test result; the criteria used to define
invasive fungal diseases; and the enrollment of patients at different
risks of developing invasive aspergillosis. As for time-varying
confounders, the definition of a positive test result by two
consecutive positive samples drastically reduced heterogeneity
between diagnostic studies; however, a more stringent definition
implies a lower sensitivity to detect invasive aspergillosis. Overall,
the evaluation of biomarker performance according to the timing
of test results was underreported in diagnostic studies. Marr et al.
found that the sensitivity of galactomannan antigenemia was
significantly decreased when anti-mold drugs are administered
[24], and the performance of b-glucan antigenemia or PCR assays
is thought to be similarly altered [21–23].
In the present study, we explored whether b-glucan
antigenemia or PCR assays may independently detect invasive
aspergillosis when risk management relies on serial blood
screening with galactomannan antigenemia. We selected all
febrile, neutropenic patients with acute myeloid leukemia from a
large clinical trial that included the prospective collection of
serum samples twice a week [25]. Because the trial design
eventually involved delaying early antifungal therapy in the
preemptive arm as compared to the empirical arm [25], we
were able to evaluate the performance of b-glucan antigenemia
and PCR assays in a homogeneous cohort with extended
duration of neutropenia before treatment. We initially evaluated
biomarker performance overall, and according to two restrictive
approaches with selection of serum samples for evaluation: an
early detection approach before treatment, and a confirmatory
diagnosis approach in presence of a positive galactomannan
antigenemia. Then, we performed a multi-state model describ-
ing simultaneously the likelihood of empirical antifungal therapy
and the risk of invasive aspergillosis during neutropenia, and we
evaluated whether b-glucan antigenemia and PCR assays may
accelerate the early detection of invasive aspergillosis when both
diagnostic information used to treat and risk factors of
developing invasive aspergillosis are controlled for.
Methods
Patients
The adult patients evaluated in this study had been enrolled in a
prospective, randomized, open-label, non-inferiority trial conduct-
ed from April 2003 to February 2006 in 13 French teaching
hospitals (ClinicalTrials.gov Identifier: NCT001190463). The
primary objective was to compare overall survival following either
empirical or preemptive antifungal therapy in patients treated for
hematological malignancies. In the empirical therapy arm,
persistent or recurrent fever after day 4 of broad spectrum
antibacterials led to the administration of antifungal therapy. In
the preemptive therapy arm, the initiation of antifungal therapy
was guided by clinical and radiological predefined criteria, and bi-
weekly blood screening with galactomannan antigenemia. Patients
received early antifungal therapy according to the trial protocol,
either amphotericin B deoxycholate (1 mg/kg/d) or liposomal
amphotericin B (3 mg/kg/d) depending on the level of creatinine
clearance and concomitant nephrotoxic drugs. Results of the
clinical trial have been reported [25]. The clinical trial and the
present study had been approved by the ethics committee of Henri
Mondor Teaching Hospital.
Of 293 patients enrolled in the trial, we selected all 185 (63%)
febrile, neutropenic patients treated with chemotherapy for acute
myeloid leukemia to constitute a homogeneous group at high risk
of developing invasive aspergillosis. Exclusions involved: 6 patients
without neutropenia; 8 neutropenic patients without any fever; 93
febrile, neutropenic patients treated for hematological malignan-
cies other than acute myeloid leukemia; and 1 patient with acute
myeloid leukemia who had no blood sample collected. As
compared to excluded patients, the homogeneous cohort selected
for the present study had prolonged neutropenia (median
duration: 23 days vs. 11 days; P,.001) and a higher risk of
developing invasive aspergillosis (11 (6.0%) vs. 1 (0.9%); P= .06),
despite a higher rate of early antifungal therapy with intravenous
amphotericin B (112 (60.5%) vs. 26 (24.1%); P,.001).
Antigen and DNA Detection Assays
Blood samples were prospectively collected twice a week during
trial enrollment, and processed to serum samples. A portion of
serum was immediately screened with ELISA Aspergillus galacto-
mannan antigenemia (Platelia Aspergillus, Biorad, France), and
GM index results were available to clinicians within 24 hours for
treatment decision according to the trial protocol [25]. The
remaining serum was stored at 270uC in two different aliquots.
For the present study, two blinded authors processed all 2,214
serum samples after trial completion. b-glucan was assayed on a
specific aliquot using the Fungitell test (Associates of Cape Cod,
Inc, Falmouth, MA) according to the manufacturer’s specifica-
tions; a positive test result was defined as a level of (1,3)-b-D glucan
$80 pg/ml. After thawing, DNA extraction was performed from
1 ml serum with the MagNA Pure LC DNA as described
previously [26]. A quantitative PCR (qPCR) assay targeting a
mitochondrial DNA sequence of Aspergillus was evaluated [27].
This test included the uracil-N-glycosylase use for preventing
amplicon contamination, and an internal control based on the
amplification of mouse DNA to minimize the risk of false-negative
test results [28–30].
Invasive Aspergillosis Case Definition
In the clinical trial, proven and probable invasive aspergilloses
were defined by an independent blinded adjudication committee
according to EORTC/MSG consensus criteria of 2002 [2].
Invasive aspergillosis was considered as ‘baseline’ for those
Performance of Aspergillosis Biomarkers
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documented by procedures before or within 24 h after the first
dose of early antifungal therapy, and ‘breakthrough’ otherwise.
Performance of b-glucan Antigenemia and PCR Assays
We initially evaluated biomarker performance as usually done
at the patient level. At the core of the evaluation is the
definition of a patient tested positive for invasive aspergillosis.
We considered that a patient with at least one positive test
result is tested positive to maximize the sensitivity of b-glucan,
qPCR, or both when used in combination. We evaluated
biomarker performance overall with use of all samples collected
during study enrollement, and according to two restrictive
approaches with selection of serum samples to underline the
importance of the timing of test results on biomarker
performance: 1) an early detection approach with selection of
samples collected after neutropenia or fever onset, and before
treatment, invasive fungal disease, or neutropenia recovery; 2) a
confirmatory diagnosis approach of a positive galactomannan
antigenemia with selection of samples collected on the same
sample or the consecutive sample of a GM index $0.5.
Then, we evaluated biomarker performance as a time-varying
predictor at the patient level. At the core of the evaluation is
whether the first positive test result with b-glucan or qPCR is
an independent predictor of invasive aspergillosis when both
diagnostic information used to treat and risk factors of
developing invasive aspergillosis are taken into account over
time. We developed a multi-state model describing the event
history of the patients in continuous time, where events with
inherent dependence are defined by the daily transitions
between 3 distinct states: (1) ‘no antifungal therapy’ (2)
‘antifungal therapy’ and (3) ‘invasive aspergillosis’ (Figure 1).
All patients entered the model in the state of ‘no antifungal
therapy’ on the first day of neutropenia or fever onset,
whichever occurred first, as it may be considered as the starting
point of invasive aspergillosis risk in febrile, neutropenic
patients. Patients in the initial state free of antifungal therapy
could: (a1) develop invasive aspergillosis (i.e., ‘baseline’ invasive
aspergillosis); (b1) get treated; or (c1) remain untreated. Once
antifungal therapy was started, patients could: (a2) develop
invasive aspergillosis despite treatment (i.e., ‘breakthrough’
invasive aspergillosis); (b2) be removed from treatment; or (c2)
remain treated. Invasive aspergillosis was the primary outcome
of the multi-state model and considered as an absorbing state
with no follow-up; otherwise, daily transitions were observed
until neutropenia recovery, candidemia or death from causes
other than invasive aspergillosis.
A semi-Markov process was used for the multi-state model,
where each transition is specified as a separate hazard function
and described by an accelerated failure time model. The choice
of accelerated failure time models was guided by empirical
findings suggesting that each hazard rate depends not only on
observed characteristics, but also on the time elapsed in each
state: (a1) the risk of invasive aspergillosis increases with
neutropenia duration in patients treated with chemotherapy
for acute myeloid leukemia [4,5]; by contrast, (a2) the risk of
invasive aspergillosis becomes flat or may even decrease during
antifungal therapy as a result of its preventive efficacy [6]; (b1)
the likelihood to start empirical antifungal therapy increases
with neutropenia duration as clinicians may suspect the risk of
invasive aspergillosis and other invasive fungal diseases; (b2) the
likelihood to stop empirical antifungal therapy increases with
treatment duration as treatment is stopped at neutropenia
recovery.
The multi-state model allowed for examination of the
independent effect of explanatory variables on each hazard
function. We checked whether the first positive galactomannan
antigenemia available to clinicians increased the likelihood to
start antifungal therapy, and we evaluated whether the first
positive test result with b-glucan or qPCR may accelerate the
early detection of invasive aspergillosis, i.e., the biomarker was
independently associated with an increased risk of invasive
aspergillosis before antifungal therapy was started. The evalu-
ation of biomarker performance was controlled for selected
confounders on each hazard function. Time-invariant confound-
ers included: age; primary antifungal prophylaxis; and preemp-
tive therapy arm of the trial. Time-varying confounders
included: daily assessment of fever above 38uC after day 4 of
fever; time to first clinical or radiological pulmonary signs; and
timing and length of stay in laminar air-flow rooms or other
protective environment rooms with high-efficiency particulate
air (HEPA) filters [31–33].
Statistical Analysis
For the evaluation of biomarker performance as usually done,
we calculated sensitivity and specificity according to the propor-
tion of patients with true and false positive and negative test
results. Ninety-five percent confidence intervals [95% CIs] for
sensitivity and specificity were estimated using exact binomial
distributions. In addition, we assessed overall biomarker perfor-
mance by calculating the Youden index (sensitivity+specificity-1)
that varies from 0 (no diagnostic accuracy) to 1 (perfect diagnostic
accuracy).
For the multi-state model, we estimated simultaneously all four
hazard functions under the specifications of each accelerated
failure time model and a Weibull parameterization of each
baseline hazard [34–36]. The family of parametric models as the
one used in this analysis not only allows the estimation of the effect
of explanatory variables on the hazard rate, but also the estimation
of the effect of the time elapsed in each state. The latter effect
known as duration dependence is estimated by means of the shape
parameter whose value describes how the hazard rate changes
over time. A shape parameter equal to 1 indicates a hazard rate
that does not vary over time. By contrast, a value above (below) 1
Figure 1. Multi-State Model of Invasive Aspergillosis and
Antifungal Therapy in Febrile, Neutropenic Patients with Acute
Myeloid Leukemia.
doi:10.1371/journal.pone.0065776.g001
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implies a low (high) variability, indicating that patients will
transition from one state to another within a relatively short (long)
time span. The regression coefficient of an explanatory variable
directly measures the proportionate change in the hazard function
for a unit change of the explanatory variable, all other things being
equal. All analyses were performed using R version 2.11.0 (R
Development Core Team, 2010).
Results
Table 1 presents the characteristics of the 185 febrile,
neutropenic patients with acute myeloid leukemia selected for
the present study as well as the risk management of invasive
aspergillosis during neutropenia.
Table 2 presents biomarker performance overall, and accord-
ing to two restrictive approaches with selection of serum samples
for evaluation. Overall (median (IQR) of 7 (5–9) samples per
patient), all 11 patients with invasive aspergillosis had at least 1
positive test result with b-glucan or qPCR: sensitivity of each
biomarker was 82% and 73%, respectively, although specificity
was below 50%. In comparison, the selection of serum samples in
an early detection approach (median (IQR) of 3 (2–5) samples per
patient) was associated with a lower performance of each
biomarker before treatment (Youden index below 0.15) as
explained by a sharp loss in sensitivity (45% and 36%,
respectively). The selection of 59 serum samples in a confirmatory
diagnosis approach of a positive galactomannan antigenemia was
associated with the best performance of each biomarker (Youden
index above 0.45) as explained by an increased specificity above
90%.
Table 3 presents the multi-state model describing the event
history of the 185 febrile, neutropenic patients in continuous time.
Several observations confirmed the relevance and validity of this
approach. The baseline hazard of invasive aspergillosis increased
with neutropenia duration before antifungal therapy was started
(Weibull shape parameter = 1.89; P,.001), and significantly
decreased during treatment (Weibull shape parameter = .97;
P,.001). According to the trial protocol, the empirical adminis-
tration of antifungal therapy was guided by the diagnostic
information available to clinicians: the hazard rate for starting
treatment increased with persistent or recurrent fever (acceleration
factor = 1.21 [95% CI, 1.16–1.26] for each day of fever after day 4
of broad spectrum antibacterials), the first day of a radiological
pulmonary sign (acceleration factor = 1.66 [95% CI, 1.37–2.02]),
or the first day of a positive galactomannan antigenemia
(acceleration factor = 1.25 [95% CI, 1.11–1.42]); the hazard rate
for stopping treatment increased with the first day of fever
resolution (acceleration factor = 1.07 [95% CI, 1.01–1.15]). In
accordance with trial results, the preemptive therapy arm halved
the hazard rate for starting treatment as compared to the empirical
therapy arm of the trial (acceleration factor for starting
treatment = 0.53 [95% CI, 0.50–0.55]), and treatment duration
was consequently decreased before neutropenia recovery (acceler-
ation factor for stopping treatment = 1.19 [95% CI, 1.11–1.28]).
In addition, the multi-state model revealed that the risk of invasive
aspergillosis before treatment was significantly decreased in
laminar air-flow rooms (acceleration factor = 0.34 [95% CI,
0.21–0.55] for each day spent in a laminar air-flow room) as
compared to non-protective environment rooms.
As for the evaluation of biomarker performance as a time-
varying predictor in the multi-state model, we found that qPCR
assay may accelerate the early detection of invasive aspergillosis,
independently of galactomannan antigenemia and other diagnos-
tic information used to start treatment during neutropenia: the first
positive test result with qPCR was an independent and significant
predictor of invasive aspergillosis before antifungal therapy was
started (P= .010), while b-glucan was not (P= .53). Similar results
of biomarker performance were found whether a higher cutoff
level (GM index $1.5) had been used to define a positive
Table 1. Characteristics of 185 febrile, neutropenic patients treated for acute myeloid leukemia and by invasive aspergillosis.
Characteristic of Patient and Risk Management of Invasive
Aspergillosis
Overall,
N =185
Invasive
Aspergillosisa,
N=11
No Invasive
Aspergillosis,
N=174 p-valueb
Age, mean (SD), yr 54 (14) 62 (8) 53 (14) .030
Female 88 (48) 5 (46) 83 (48) .89
Remission-induction chemotherapy for new diagnosis or first relapse 134 (72) 10 (91) 124 (71) .29
Duration of neutrophil count ,500/mm3, median (IQR), days 23 (16–30) 26 (20–32) 23 (15–30) .17
Protective environment room:
Laminar air-flow room 63 (34) 1 (9) 62 (36)
Other protective environment room with HEPA filters 39 (21) 1 (9) 38 (22)
Non-protective environment room 83 (45) 9 (82) 74 (42) .013
Primary antifungal prophylaxisc 77 (42) 4 (36) 73 (42) .76
Antifungal therapy with intravenous amphotericin Bd 112 (61) 4 (36) 108 (62) .11
Candidemia 4 (2) 0 4 (2) 1.00
Death at end of studye 8 (4) 2 (18) 6 (3) .07
Abbreviations: IA: invasive aspergillosis; IQR: interquartile range; HEPA: High-Efficiency Particulate Air.
aOf 11 IA, the independent blinded adjudication committee of the trial defined 2 proven IA and 9 probable IA according to international consensus definitions of 2002.
bBy chi-square test or exact Fisher test for binary variables; by Wilcoxon sum-rank test for continuous variables.
cProphylaxis included oral amphotericin B (n = 54), fluconazole (n = 23), and/or itraconazole (n = 10).
dOf 11 IA, 7 IA were documented by procedures before or within 24 h after the first dose of antifungal therapy, and 4 breakthrough IA occurred after antifungal therapy
was started.
eCauses of death included 2 IA, 4 bacterial sepsis, 1 cardiogenic shock, and 1 coma of unknown origin. Follow-up was censored at 14 days after neutropenia recovery or
at 60 days of neutropenia.
doi:10.1371/journal.pone.0065776.t001
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galactomannan antigenemia in serial blood screening (data not
shown).
Discussion
Meta-analyses of biomarker performance to detect invasive
aspergillosis found a marked heterogeneity between diagnostic
studies [19–23]. Among potential sources of heterogeneity, Marr
et al. found that the sensitivity of galactomannan antigenemia was
significantly decreased by the administration of anti-mold drugs
[24], and recommended evaluating biomarker performance in a
dynamic approach accounting for the timing of test results [7]. To
our knowledge, we present the first multi-state model allowing the
evaluation of biomarker performance as a time-varying predictor
of invasive aspergillosis before treatment, while multiple sources of
heterogeneity may be controlled for. When the multi-state model
was applied to a homogeneous cohort of 185 febrile, neutropenic
patients screened for galactomannan antigenemia twice a week,
we found that PCR assays may accelerate the early detection of
invasive aspergillosis before antifungal therapy was started, while
b-glucan would not. By contrast, the usual evaluation framework
was unable to distinguish clinical benefits of b-glucan or PCR
assays.
We confirm that the performance of biomarkers dramatically
depends on the timing of test results relative to an evolving risk of
invasive aspergillosis. When considering all serum samples
collected during study enrollment, the sensitivity of b-glucan
(82%) and qPCR (73%) to detect invasive aspergillosis was in the
range of pooled estimates (77% [95% CI, 67–84] without
difference in the detection of invasive aspergillosis and candidemia
[22], and 88% [95% CI, 75–94] [21], respectively), although
specificity of both biomarkers (45%) was significantly lower (85%
[95% CI, 80–90] for b-glucan [22], and 75% [95% CI, 63–84] for
PCR [21]). Such discrepancy may be attributed to the stringent
case definition of invasive aspergillosis used in the trial, and false
positive test results occurring outside the risk window of invasive
aspergillosis, i.e., about half samples were collected before
neutropenia/fever onset, during antifungal therapy, or after
neutropenia recovery.
In the usual evaluation framework, two approaches allow
decreasing false positive rates, while somewhat coping with the
timing of test results. As advocated in recent meta-analyses, the
definition of a positive test result may be restricted to two
consecutive positive samples: specificity improved by about 10%
for both b-glucan [23] and PCR assays [21]; however, biomarker
sensitivity to detect invasive aspergillosis decreased by about the
same extent, and two consecutive samples imply delaying
antifungal therapy in patients who should benefit. Alternatively,
evaluation may be restricted to serum samples collected in the risk
window of invasive aspergillosis. We found that specificity of both
biomarkers increased from 45% to 66%, although at the expense
of a sharp loss in sensitivity. In addition, when risk management
involves blood screening with galactomannan antigenemia twice a
week, reserving b-glucan and/or PCR assays for confirming a
positive galactomannan antigenemia may be a more cost-effective
use of scare resources as the best overall performance was achieved
from the drastic selection of these serum samples (4%, 59/1,534).
The usual evaluation framework is misleading on biomarker
performance because neither the evolving risk of invasive
aspergillosis nor the related kinetics of biomarkers are actually
taken into account [7]. The use of serial blood screening was
mainly supported by the general finding that the first positive
galactomannan antigenenmia precedes clinical and radiological
pulmonary signs of invasive aspergillosis [8,13,37]. Given the
expected correlation of serum biomarkers among each other, serial
blood screening would primarily benefit from additional biomark-
ers that accelerate the early detection of invasive aspergillosis,
although the kinetics of biomarkers were barely compared [9–11].
Table 2. Performance of b-glucan and qPCR, overall and according to two restrictive approaches of invasive aspergillosis diagnosis
with selection of serum samples.
Definition of a Patient Tested Positive
for Invasive Aspergillosis
No. patients tested
positive/No.
patients with IA
Sensitivity, %
(95% CI)
No. patients tested
negative/No.
patients without
IA
Specificity, %
(95% CI) Youden indexa
Overall performance: all serum samples collected during study enrollment (n =1,534)
$1 positive test with ß-glucan 9/11 82 (48–98) 79/174 45 (38–53) 0.27
$1 positive test with qPCR 8/11 73 (39–94) 79/174 45 (38–53) 0.18
$1 positive test with ß-glucan or qPCR 11/11 100 (72–100) 39/174 22 (16–29) 0.22
Early detection of IA: selection of serum samples before early antifungal therapyb (n =747)
$1 positive test with ß-glucan 5/11 45 (17–77) 113/172 66 (58–73) 0.11
$1 positive test with qPCR 4/11 36 (11–69) 113/172 66 (58–73) 0.02
$1 positive test with ß-glucan or qPCR 7/11 64 (31–89) 76/172 44 (37–52) 0.08
Confirmatory diagnosis of IA: selection of serum samples in presence of a positive GM test resultc (n = 59)
$1 positive test with ß-glucan 6/11 55 (23–83) 159/174 91 (86–95) 0.46
$1 positive test with qPCR 6/11 55 (23–83) 162/174 93 (88–96) 0.48
$1 positive test with ß-glucan or qPCR 7/11 64 (31–89) 152/174 87 (81–92) 0.51
Abbreviations: IA: Invasive Aspergillosis; GM: Aspergillus galactomannan antigenemia; ß-glucan: (1,3)-b-D glucan antigenemia; qPCR: PCR assay targeting Aspergillus
fumigatus mitochondrial DNA.
aYouden index is calculated as follows: Sensitivity+Specificity-1; and varies from 0 (no diagnostic accuracy) to 1 (perfect diagnostic accuracy).
bSelection of serum samples after neutropenia/fever onset, and before antifungal therapy, invasive fungal infection, or neutropenia recovery.
cSelection of serum samples collected on the same sample or the consecutive sample of a GM positive result as defined by a GM index $0.5 according to the
manufacturer’s specifications.
doi:10.1371/journal.pone.0065776.t002
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Our multi-state model results provide strong rationale for
prospective studies to test whether a refined preemptive therapy,
guided by clinical, radiological, and bi-weekly blood screening
with galactomannan antigenemia and a standardized PCR assay is
not inferior to empirical therapy.
Our diagnostic study presents several strengths: a prospective,
multicenter design; a homogeneous cohort of 185 febrile,
neutropenic patients with acute myeloid leukemia; a central,
blinded assessment of serum biomarkers; and the definition of
invasive fungal diseases according to EORTC/MSG consensus
criteria. As a limitation, the frequency of invasive fungal diseases
was relatively low, and we could not model the competing risk of
candidemia. However, invasive aspergillosis is the dominant
invasive fungal disease in hematological wards, and candidemia
is of less concern because of the broad use of primary prophylaxis
with anti-yeast activity [38,39]. Moreover, the evaluation of
biomarker performance was controlled for multiple sources of
heterogeneity in the risk management of invasive aspergillosis
during neutropenia. Besides empirical antifungal therapy, the risk
of invasive aspergillosis was significantly decreased in laminar air-
flow rooms [31–33], while primary prophylaxis may also have
been associated with a risk reduction of invasive aspergillosis
whether drugs with anti-mold activity had been used [40].
Overall, our study results support the recent call to report the
timing of test results in diagnostic studies [21–23]. However, the
risk of invasive aspergillosis is a complex time function of
neutropenia duration and risk management. Accordingly, the
comparison of biomarker performance, and more broadly any
preventative strategy of invasive fungal diseases, would benefit
from the complete reporting of all known time-varying confound-
ers related to the diagnosis and management of invasive fungal
diseases.
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